Heteroaromatic ring compound and application thereof
By designing heterocyclic compounds as WRN inhibitors, the treatment gap in existing technologies for cancers related to WRN helicase and microsatellite instability has been filled, achieving effective treatment for WRN helicase-mediated diseases, especially MSI-H cancer.
Patent Information
- Application Number
- CN202510586362.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2025-01-13
- Filing Date
- 2025-05-08
- Publication Date
- 2025-11-11
Smart Images

Figure CN120923473A_ABST
Abstract
Description
[0001] Cross-reference to related applications
[0002] This application claims priority and benefits to the following Chinese patent applications filed with the China National Intellectual Property Administration: Chinese Patent Application No. 202410570404.8, filed May 9, 2024; Chinese Patent Application No. 202411083297.2, filed August 8, 2024; Chinese Patent Application No. 202411383223.0, filed September 30, 2024; and Chinese Patent Application No. 202510050853.4, filed January 13, 2025. The entire contents of the above patent applications are incorporated herein by reference. Technical Field
[0003] This disclosure relates to heterocyclic aromatic compounds or pharmaceutically acceptable salts thereof, methods of their preparation, pharmaceutical compositions containing them, and their use as WRN inhibitors in the prevention or treatment of related diseases. Background Technology
[0004] Helicases are a class of enzymes that untangle double-stranded nucleotides. They utilize the energy released during the hydrolysis of nucleoside triphosphates to move along the nucleic acid chain, thereby untangling and separating the nucleic acid double strands. As representatives of DNA helicases, the RecQ helicase family plays a significant role in maintaining chromosomal genome and telomere stability. During DNA replication, they catalyze the unwinding of double-stranded DNA, completing DNA repair and thus maintaining genome integrity.
[0005] RecQ family helicases are highly conserved throughout evolution, and their functions are involved in a variety of DNA metabolic processes, playing a crucial role in maintaining genome stability. The loss of function of BLM, WRN, and RecQ4, three of the five RecQ family helicases in humans, leads to BLM syndrome, WRN syndrome, and Rothmund-Thomson syndrome, respectively. These diseases all exhibit high genomic instability, chromosomal abnormalities, and susceptibility to DNA damage at the molecular level.
[0006] WRN and RecQ1 are two of the most representative RecQ helicases. WRN includes an exonuclease domain in addition to its unwinding domain. Werner syndrome (WS) is an autosomal recessive genetic disorder characterized by accelerated clinical aging, resulting in a lifespan of less than 50 years. WS helicase nuclease (WRN) is involved in many important pathways, including DNA replication, recombination, and repair. WRN can unwind non-canonical secondary DNA structures encountered during replication and recombination; mutations in WRN can cause chromosomal instability disorders such as Werner syndrome. Under normal circumstances, WRN depletion leads to DNA double-strand breaks in MSI cells, resulting in cell cycle arrest and / or apoptosis. Studies have shown a strong synthetic lethal relationship between WRN helicase and microsatellite instability-high (MSI-H) cancers. WRN forms a synthetic lethal relationship with the DNA mismatch repair protein MutL homolog 1 (MLH1), and MLH1 loss is associated with microsatellite instability (MSI).
[0007] Microsatellites are simple repetitive sequences of less than 10 nucleotides in the genome. Defects in DNA mismatch repair (MMR) caused by gene mutations or promoter hypermethylation can lead to hypermutations in nucleotide repeat regions (microsatellites), a condition known as microsatellite instability (MSI). MSI can promote the development of various cancers, including colon cancer (15%), gastric cancer (22%), endometrial cancer (20%-30%), and ovarian cancer (12%), with 45%-60% of these not responding to immune checkpoint blockade. Therefore, MSI tumors require novel treatment approaches. In two genome-wide gene inactivation studies using CRISPR or RNA interference, wRN was identified as the most significant dependency in MSI-H cells, and this dependency was associated with unwinding activity but not with the nuclease function of wRN. These findings, coupled with the good tolerance of microsatellite stable (MSS) cancer cells to wRN silencing, demonstrate that wRN is a potential specific target for the treatment of MSI tumors.
[0008] Given the huge unmet clinical needs, the development of small molecule inhibitors targeting WRN has broad application prospects. Summary of the Invention
[0009] This disclosure relates to compounds of formula (I) or pharmaceutically acceptable salts thereof.
[0010]
[0011] Among them, R 3 Selected from 4-membered heterocyclic groups, 7-12-membered heterocyclic groups, C6-C 10Aryl or 5-10 membered heteroaryl, wherein the 4-membered heterocyclic group, 7-12 membered heterocyclic group, C6-C 10 Aryl or 5-10 heteroaryl groups may be substituted;
[0012] X is selected from N or CR x ;
[0013] Y is selected from N or CR y ;
[0014] Z is selected from N or CR. z ;
[0015] Alternatively, Y and Z, together with their connected bonds, form a 5-6 membered heteroaromatic ring or a 5-6 membered heterocyclic ring, which may optionally be substituted.
[0016] The condition is that X, Y, and Z are not all N at the same time;
[0017] R x R y and R z Each is independently selected from H, halogen, cyano, amino, NHC(=O)C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, C1-C6 haloalkyl or C3-C6 cycloalkyl;
[0018] L 1 Selected from bond, O, S, NR, CH2 or OCH2, wherein CH2 or OCH2 is optionally substituted with a halogen;
[0019] R is selected from hydrogen, C1-C3 alkyl, or C1-C3 haloalkyl;
[0020] R 1 Selected from C3-C8 cycloalkyl, C1-C6 alkyl, C6-C 10 aryl, 5-10 membered heteroaryl or 4-12 membered heterocyclic, wherein the C3-C8 cycloalkyl, C1-C6 alkyl, C6-C 10 Aryl, 5-10 membered heteroaryl, or 4-12 membered heterocyclic group may be substituted;
[0021] R 2 Selected from C3-C8 cycloalkyl, C5-C 10 Cycloalkenyl, C6-C 10Aryl, C1-C6 alkyl, amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, NH(C3-C8 cycloalkyl), N(C1-C6 alkyl)(C3-C8 cycloalkyl), C2-C6 alkenyl, -S-C1-C6 alkyl, C1-C6 alkoxy, -O-C3-C8 cycloalkyl, 4-12 membered heterocyclic or 5-10 membered heteroaryl, wherein the C3-C8 cycloalkyl, C5-C 10 Cycloalkenyl, C6-C 10 Aryl, C1-C6 alkyl, amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, NH(C3-C8 cycloalkyl), N(C1-C6 alkyl)(C3-C8 cycloalkyl), C2-C6 alkenyl, -S-C1-C6 alkyl, C1-C6 alkoxy, -O-C3-C8 cycloalkyl, 4-12 membered heterocyclic or 5-10 membered heteroaryl, may be optionally substituted; or R 2 Y and the carbon atoms they are attached to form C6-C. 10 Aromatic rings, C5-C 10 Cycloolefin rings, 5-6 membered heteroaromatic rings, or 5-6 membered heterocycles, wherein the C6-C 10 Aromatic rings, C5-C 10 Cycloolefin rings, 5-6 membered heteroaromatic rings, or 5-6 membered heterocycles may be optionally substituted;
[0022] L 2 Selected from -C(=O)NH-, -C(=S)NH-, -S(=O)2NH-, 1,2,3-triazolyl, oxadiazolyl, imidazolyl, tetrazolyl, pyrazolyl, -NHC(=O)NH-, -NHC(=O)O-, -CH(CF3)NH- or
[0023] Q is selected from Q 1 Q 2 Q 3 Or Q 4 ;
[0024] Q 1 yes in, represent It is either (Z) configuration or (E) configuration;
[0025] X 3 Selected from O, NH or NR 5 ;
[0026] R 4 Selected from C1-C6 alkyl, C3-C6 cycloalkyl or 4-6 membered heterocyclic groups, wherein the C1-C6 alkyl, C3-C6 cycloalkyl or 4-6 membered heterocyclic groups may optionally be substituted;
[0027] R5 It is selected from cyano, C(=O)C1-C6 alkyl, C1-C6 alkyl, C3-C6 cycloalkyl or 4-6 membered heterocyclic group, wherein the C(=O)C1-C6 alkyl, C1-C6 alkyl, C3-C6 cycloalkyl or 4-6 membered heterocyclic group may optionally be substituted;
[0028] Q 2 yes in, represent It is either (Z) configuration or (E) configuration;
[0029] Q 3 yes
[0030] Q 4 yes Among them, R a It is a C1-C6 alkyl group, wherein the C1-C6 alkyl group may optionally be substituted.
[0031] In some implementation schemes, R 3 Selected from 4-membered heterocyclic groups, 7-12-membered heterocyclic groups, C6-C 10 Aryl or 5-10 membered heteroaryl, wherein the 4-membered heterocyclic group, 7-12 membered heterocyclic group, C6-C 10 Aryl or 5-10 heteroaryl groups are selectively coated with R. 3a Replace; R 3a Selected from halogen, cyano, hydroxy, amino, carboxyl, oxo, -S-C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, -S-C1-C6 alkyl, -O-C3-C6 cycloalkyl, C(=O)NH2, C(=O)NH(C1-C6 alkyl), C(=O)N(C1-C6 alkyl)2, phenoxy, C(=O)C1-C6 alkyl or S(O)2C1- C6 alkyl, wherein the amino group, -S-C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, -S-C1-C6 alkyl, -O-C3-C6 cycloalkyl, C(=O)NH2, C(=O)NH(C1-C6 alkyl), C(=O)N(C1-C6 alkyl)2, phenoxy, C(=O)C1-C6 alkyl or S(O)2C1-C6 alkyl may optionally be substituted.
[0032] In some implementation schemes, R 3 Selected from 4-membered heterocyclic groups, 7-12-membered heterocyclic groups, C6-C 10 Aryl or 5-10 membered heteroaryl, wherein the 4-membered heterocyclic group, 7-12 membered heterocyclic group, C6-C 10 Aryl or 5-10 heteroaryl groups are selectively coated with R. 3a Replace; R 3aThe group is selected from halogen, cyano, hydroxy, amino, carboxyl, oxo, -S-C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, -S-C1-C6 alkyl, -O-C3-C6 cycloalkyl, C(=O)NH2, C(=O)NH(C1-C6 alkyl), C(=O)N(C1-C6 alkyl)2 or phenoxy, wherein the amino, -S-C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, -S-C1-C6 alkyl, -O-C3-C6 cycloalkyl, C(=O)NH2, C(=O)NH(C1-C6 alkyl), C(=O)N(C1-C6 alkyl)2 or phenoxy may optionally be substituted.
[0033] In some implementation schemes, R 3a Selected from halogen, cyano, hydroxy, amino, carboxyl, oxo, -S-C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, -S-C1-C6 alkyl, -O-C3-C6 cycloalkyl, C(=O)NH2, C(=O)NH(C1-C6 alkyl), C(=O)N(C1-C6 alkyl)2, phenoxy, C(=O)C1-C6 alkyl or S(O)2C1 -C6 alkyl, wherein the amino group, -S-C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, -S-C1-C6 alkyl, -O-C3-C6 cycloalkyl, C(=O)NH2, C(=O)NH(C1-C6 alkyl), C(=O)N(C1-C6 alkyl)2, phenoxy, C(=O)C1-C6 alkyl or S(O)2C1-C6 alkyl is optionally R 3b Replace; R 3b Selected from halogens or C1-C6 alkyl groups.
[0034] In some implementation schemes, R 3a Selected from halogen, cyano, hydroxy, amino, carboxyl, oxo, -S-C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, -S-C1-C6 alkyl, -O-C3-C6 cycloalkyl, C(=O)NH2, C(=O)NH(C1-C6 alkyl), C(=O)N(C1-C6 alkyl)2 or phenoxy, wherein the amino, -S-C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, -S-C1-C6 alkyl, -O-C3-C6 cycloalkyl, C(=O)NH2, C(=O)NH(C1-C6 alkyl), C(=O)N(C1-C6 alkyl)2 or phenoxy is optionally R 3b Replace; R 3b Selected from halogens or C1-C6 alkyl groups.
[0035] In some implementation schemes, R 3 Selected from 4-membered heterocyclic groups, wherein the 4-membered heterocyclic group is optionally R 3a replace.
[0036] In some implementation schemes, R 3 Selected from oxetane or azirnebutane, wherein the oxetane or azirnebutane is optionally R 3a replace.
[0037] In some implementation schemes, R 3 Selected from oxetane or azirnebutane, wherein the azirnebutane is optionally R 3a replace.
[0038] In some implementation schemes, R 3a Selected from halogens, amino groups, C1-C6 alkyl groups, C1-C6 alkoxy groups, -S-C1-C6 alkyl groups, C(=O)NH2, C(=O)NH(C1-C6 alkyl), C(=O)N(C1-C6 alkyl)2, C(=O)C1-C6 alkyl, or S(O)2C1-C6 alkyl groups, wherein the amino group, C1-C6 alkyl group, C1-C6 alkoxy group, -S-C1-C6 alkyl group, C(=O)NH2, C(=O)NH(C1-C6 alkyl), C(=O)N(C1-C6 alkyl)2, C(=O)C1-C6 alkyl, or S(O)2C1-C6 alkyl group is optionally R 3b replace.
[0039] In some implementation schemes, R 3a Selected from halogens, amino groups, C1-C6 alkyl groups, C1-C6 alkoxy groups, -S-C1-C6 alkyl groups, C(=O)NH2, C(=O)NH(C1-C6 alkyl) or C(=O)N(C1-C6 alkyl)2, wherein the amino group, C1-C6 alkyl group, C1-C6 alkoxy group, -S-C1-C6 alkyl group, C(=O)NH2, C(=O)NH(C1-C6 alkyl) or C(=O)N(C1-C6 alkyl)2 is optionally R 3b replace.
[0040] In some implementation schemes, R 3a Selected from C1-C6 alkyl, C(=O)C1-C6 alkyl, or S(O)2C1-C6 alkyl, wherein the C1-C6 alkyl, C(=O)C1-C6 alkyl, or S(O)2C1-C6 alkyl is optionally R 3b replace.
[0041] In some implementation schemes, R 3a Selected from C1-C6 alkyl groups, wherein the C1-C6 alkyl groups are optionally R 3b replace.
[0042] In some implementation schemes, R 3a Selected from C1-C3 alkyl, C(=O)C1-C3 alkyl, or S(O)2C1-C3 alkyl, wherein the C1-C3 alkyl, C(=O)C1-C3 alkyl, or S(O)2C1-C3 alkyl is optionally R 3b replace.
[0043] In some implementation schemes, R 3a Selected from C1-C3 alkyl, C(=O)C1-C3 alkyl, or S(O)2C1-C3 alkyl, wherein the C1-C3 alkyl is optionally R 3b replace.
[0044] In some implementation schemes, R 3a Selected from methyl, ethyl, C(=O)CH3 or S(O)2CH3, wherein the methyl, ethyl, C(=O)CH3 or S(O)2CH3 is optionally R 3b replace.
[0045] In some implementation schemes, R 3a Selected from C1-C3 alkyl groups, wherein the C1-C3 alkyl groups are optionally R 3b replace.
[0046] In some implementation schemes, R 3b Selected from halogens.
[0047] In some implementation schemes, R 3b Selected from fluorine.
[0048] In some implementation schemes, R 3 Selected from
[0049] In some implementation schemes, R 3 Selected from
[0050] In some implementation schemes, R 3 Selected from In some implementations, X is selected from N or CR. x Y is selected from N or CR y Z is selected from N or CR z The condition is that X, Y, and Z are not all N at the same time.
[0051] In some implementations, X is selected from N, Y is selected from N, and Z is selected from CR. z .
[0052] In some implementation schemes, R z Selected from H, halogen, amino, C1-C6 alkyl or NHC(=O)C1-C6 alkyl.
[0053] In some implementation schemes, R z Selected from H.
[0054] In some implementations, X is selected from N, Y is selected from N, and Z is selected from CH.
[0055] In some embodiments, Y and Z, together with their linked bonds, form a 5-6 membered heteroaromatic ring or a 5-6 membered heterocycle, which is optionally surrounded by R. 7 Replace, R 7 Selected from halogens, cyano groups, amino groups, NHC(=O)C1-C6 alkyl groups, C1-C6 alkyl groups, C1-C6 haloalkyl groups, or C3-C6 cycloalkyl groups; or two R groups attached to adjacent ring atoms. 7 Together with the atoms they are attached to, they form C5-C. 10 Cyclic olefin ring, C6-C 10 Aromatic rings, 4-12 membered heterocyclic rings or 5-10 membered heteroaromatic rings, wherein C5-C 10 Cyclic olefin ring, C6-C 10 Aromatic rings, 4-12 membered heterocyclic rings, or 5-10 membered heteroaromatic rings may be substituted.
[0056] In some implementation schemes, R 7 Selected from halogens, cyano groups, amino groups, NHC(=O)C1-C6 alkyl groups, C1-C6 alkyl groups, C1-C6 haloalkyl groups, or C3-C6 cycloalkyl groups; or two R groups attached to adjacent ring atoms. 7 Together with the atoms they are attached to, they form C5-C. 10 Cyclic olefin ring, C6-C 10 Aromatic rings, 4-12 membered heterocyclic rings or 5-10 membered heteroaromatic rings, wherein C5-C 10 Cyclic olefin ring, C6-C 10 Aromatic rings, 4-12 quinary heterocyclic rings, or 5-10 quinary heterocyclic rings can be selected by R. 7a Replace; R 7a It is selected from halogen, cyano, amino, NHC(=O)C1-C6 alkyl, C1-C6 alkyl, C1-C6 haloalkyl or C3-C6 cycloalkyl.
[0057] In some implementations, L 1 Selected from key, O, S, or NR.
[0058] In some implementations, L 1 It is O.
[0059] In some implementation schemes, R 1 Selected from C3-C8 cycloalkyl, C1-C6 alkyl, C6-C 10 aryl, 5-6 membered heteroaryl or 5-6 membered heterocyclic, wherein the C3-C8 cycloalkyl, C1-C6 alkyl, C6-C10 Aryl, 5-6 membered heteroaryl or 5-6 membered heterocyclic group are optionally replaced by R 1a Replace, R 1a It is selected from halogen, deuterium, cyano, hydroxyl, amino, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, oxo, -S-C1-C6 alkyl, -O-C3-C8 cycloalkyl, -S-C3-C8 cycloalkyl or carboxyl.
[0060] In some implementation schemes, R 1 Selected from C3-C8 cycloalkyl, C6-C 10 aryl or 5-6 heteroaryl, wherein the C3-C8 cycloalkyl, C6-C 10 Aryl or 5-6 quinone heteroaryl groups are selectively substituted with R. 1a replace.
[0061] In some implementation schemes, R 1 Selected from C6-C 10 Aryl.
[0062] In some implementation schemes, R 1 Selected from phenyl.
[0063] In some implementation schemes, R 2 Selected from C3-C8 cycloalkyl, C5-C 10 Cycloalkenyl, C6-C 10 Aryl, C1-C6 alkyl, amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, NH(C3-C8 cycloalkyl), N(C1-C6 alkyl)(C3-C8 cycloalkyl), C2-C6 alkenyl, -S-C1-C6 alkyl, C1-C6 alkoxy, -O-C3-C8 cycloalkyl, 4-12 membered heterocyclic or 5-10 membered heteroaryl, wherein the C3-C8 cycloalkyl, C5-C 10 Cycloalkenyl, C6-C 10 Aryl, C1-C6 alkyl, amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, NH(C3-C8 cycloalkyl), N(C1-C6 alkyl)(C3-C8 cycloalkyl), C2-C6 alkenyl, -S-C1-C6 alkyl, C1-C6 alkoxy, -O-C3-C8 cycloalkyl, 4-12 membered heterocyclic or 5-10 membered heteroaryl, optionally with R 2a Replace; or R 2 Y and the carbon atoms they are attached to form C6-C. 10 Aromatic rings, C5-C 10 Cycloolefin rings, 5-6 membered heteroaromatic rings, or 5-6 membered heterocycles, wherein the C6-C 10 Aromatic rings, C5-C 10 Cycloolefin rings, 5-6 membered heteroaromatic rings, or 5-6 membered heterocycles may be selectively replaced by R.6 replace;
[0064] R 2a The group is selected from hydroxyl, oxo, halogen, C1-C6 alkyl, phenyl, C1-C6 alkoxy, C3-C6 cycloalkyl, cyano, amino, carboxyl, -S-C1-C6 alkyl, -S-C3-C8 cycloalkyl or -O-C3-C8 cycloalkyl, wherein the C1-C6 alkyl, phenyl, C1-C6 alkoxy, C3-C6 cycloalkyl, amino, -S-C1-C6 alkyl, -S-C3-C8 cycloalkyl or -O-C3-C8 cycloalkyl may optionally be substituted;
[0065] R 6 Selected from halogens, cyano groups, amino groups, NHC(=O)C1-C6 alkyl groups, C1-C6 alkyl groups, C1-C6 haloalkyl groups, or C3-C6 cycloalkyl groups; or two R groups attached to adjacent ring atoms. 6 Together with the atoms they are attached to, they form C5-C. 10 Cyclic olefin ring, C6-C 10 Aromatic rings, 4-12 membered heterocyclic rings or 5-10 membered heteroaromatic rings, wherein C5-C 10 Cyclic olefin ring, C6-C 10 Aromatic rings, 4-12 membered heterocyclic rings, or 5-10 membered heteroaromatic rings may be substituted.
[0066] In some implementation schemes, R 2a Selected from hydroxyl, oxo, halogen, C1-C6 alkyl, phenyl, C1-C6 alkoxy, C3-C6 cycloalkyl, cyano, amino, carboxyl, -S-C1-C6 alkyl, -S-C3-C8 cycloalkyl, or -O-C3-C8 cycloalkyl, wherein the C1-C6 alkyl, phenyl, C1-C6 alkoxy, C3-C6 cycloalkyl, amino, -S-C1-C6 alkyl, -S-C3-C8 cycloalkyl, or -O-C3-C8 cycloalkyl is optionally R 2b Replace; R 2b Selected from halogens or C1-C6 alkyl groups.
[0067] In some implementation schemes, R 6 Selected from halogens, cyano groups, amino groups, NHC(=O)C1-C6 alkyl groups, C1-C6 alkyl groups, C1-C6 haloalkyl groups, or C3-C6 cycloalkyl groups; or two R groups attached to adjacent ring atoms. 6 Together with the atoms they are attached to, they form C5-C. 10 Cyclic olefin ring, C6-C 10 Aromatic rings, 4-12 membered heterocyclic rings or 5-10 membered heteroaromatic rings, wherein C5-C 10 Cyclic olefin ring, C6-C 10 Aromatic rings, 4-12 quinary heterocyclic rings, or 5-10 quinary heterocyclic rings can be selected by R. 6a Replace, R6a It is selected from halogen, cyano, amino, NHC(=O)C1-C6 alkyl, C1-C6 alkyl, C1-C6 haloalkyl or C3-C6 cycloalkyl.
[0068] In some implementation schemes, R 2 Selected from C1-C6 alkyl, amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, NH(C3-C8 cycloalkyl), N(C1-C6 alkyl)(C3-C8 cycloalkyl), C2-C6 alkenyl, -S-C1-C6 alkyl, or C1-C6 alkoxy, wherein the C1-C6 alkyl, amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, NH(C3-C8 cycloalkyl), N(C1-C6 alkyl)(C3-C8 cycloalkyl), C2-C6 alkenyl, -S-C1-C6 alkyl, or C1-C6 alkoxy is optionally R 2a replace.
[0069] In some implementation schemes, R 2 Selected from C1-C6 alkyl groups, wherein the C1-C6 alkyl groups are optionally R 2a replace.
[0070] In some implementation schemes, R 2 Selected from C1-C4 alkyl groups, wherein the C1-C4 alkyl groups are optionally R 2a replace.
[0071] In some implementation schemes, R 2 Selected from methyl, ethyl, or tert-butyl, wherein the methyl, ethyl, or tert-butyl group is optionally R 2a replace.
[0072] In some implementation schemes, R 2a Selected from hydroxyl, halogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, cyano, amino, or -S-C1-C6 alkyl, wherein the C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, amino, or -S-C1-C6 alkyl is optionally R 2b replace.
[0073] In some implementation schemes, R 2a Selected from halogens or C3-C6 cycloalkyl groups, wherein the C3-C6 cycloalkyl group is optionally R 2b replace.
[0074] In some implementation schemes, R 2a Selected from halogens or C3-C4 cycloalkyl groups.
[0075] In some implementation schemes, R 2a Selected from fluorine or cyclopropyl.
[0076] In some implementation schemes, R 2 Selected from
[0077] In some implementations, L 2 Selected from -C(=O)NH-, -C(=S)NH-, Or -S(=O)2NH-.
[0078] In some implementations, L 2 Selected from -C(=O)NH-.
[0079] In some implementations, Q is selected from Q 1 Q 1 yes in, represent It is either (Z) configuration or (E) configuration.
[0080] In some implementation schemes, Q 1 yes
[0081] In some implementation schemes, X 3 Selected from O or NH.
[0082] In some implementation schemes, X 3 Selected from O.
[0083] In some implementation schemes, R 4 Selected from C1-C6 alkyl, C3-C6 cycloalkyl, or 4-6 membered heterocyclic groups, wherein the C1-C6 alkyl, C3-C6 cycloalkyl, or 4-6 membered heterocyclic group is optionally R 4a Replace, where R 4a It is selected from halogen, cyano, hydroxy, amino, C1-C6 alkyl or C1-C6 alkoxy.
[0084] In some implementation schemes, R 4 Selected from C1-C6 alkyl or 4-6 membered heterocyclic groups.
[0085] In some implementation schemes, R 4 Selected from C1-C3 alkyl groups.
[0086] In some implementation schemes, R 4 Selected from methyl.
[0087] In some implementation schemes, R 5 Selected from cyano, C(=O)C1-C6 alkyl, C1-C6 alkyl, C3-C6 cycloalkyl, or 4-6 membered heterocyclic groups, wherein the C(=O)C1-C6 alkyl, C1-C6 alkyl, C3-C6 cycloalkyl, or 4-6 membered heterocyclic group is optionally R 5a Replace; R5a It is selected from halogen, cyano, hydroxy, amino, C1-C6 alkyl or C1-C6 alkoxy.
[0088] In some implementations, Q is
[0089] In some embodiments, the compounds of formula (I) of this disclosure are selected from the following compounds:
[0090]
[0091] On the other hand, this disclosure provides pharmaceutical compositions comprising a compound of formula (I) of this disclosure or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
[0092] On the other hand, this disclosure provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for inhibiting WRN.
[0093] In some implementations, the intended use is for treating cancer.
[0094] On the other hand, this disclosure provides a method for inhibiting WRN, which includes the step of contacting a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, with WRN.
[0095] On the other hand, this disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, which is used as a WRN inhibitor.
[0096] On the other hand, this disclosure provides a method for treating diseases mediated by WRN helicase in mammals, comprising administering to a mammal in need of treatment, preferably a human, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
[0097] On the other hand, this disclosure provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for the prevention or treatment of WRN helicase-mediated diseases.
[0098] On the other hand, this disclosure provides the use of compounds of formula (I) or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the prevention or treatment of WRN helicase-mediated diseases.
[0099] On the other hand, this disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for the prevention or treatment of WRN helicase-mediated diseases.
[0100] In some implementations, the disease mediated by WRN helicase is selected from cancer or Werner syndrome.
[0101] On the other hand, this disclosure provides that the compound of formula (I) or a pharmaceutically acceptable salt thereof can be used as a medicine, particularly for treating conditions or diseases that can be treated by WRN inhibition.
[0102] On the other hand, this disclosure provides that the compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is used to treat cancer.
[0103] On the other hand, this disclosure provides a method for modulating WRN activity in a patient, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
[0104] On the other hand, this disclosure provides a method for inhibiting WRN in a patient, wherein the method includes administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
[0105] On the other hand, this disclosure provides a method for treating a condition or disease that can be treated in a patient by WRN inhibition, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
[0106] On the other hand, this disclosure provides a method of treating a patient with cancer, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
[0107] On the other hand, this disclosure provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the preparation of a medicament.
[0108] On the other hand, this disclosure provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for treating cancer.
[0109] On the other hand, this disclosure provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for treating diseases that can be treated by WRN inhibition.
[0110] Terminology Definitions and Explanations
[0111] Unless otherwise stated, the terms used in this disclosure have the following meanings: the definitions of groups and terms recorded in this disclosure, including their definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, definitions of specific compounds in the examples, etc., can be arbitrarily combined and combined with each other. A particular term should not be considered uncertain or unclear unless specifically defined, but should be understood in accordance with its ordinary meaning in the art. When trade names appear herein, they are intended to refer to the corresponding product or its active ingredient.
[0112] In this article Indicates the connection site.
[0113] Unless otherwise specified, use wedge keys and virtual wedge keys. The absolute configuration representing the center of a solid.
[0114] In this article The representation is either (Z) configuration or (E) configuration, for example... The representative is the (Z) configuration. or (E) configuration
[0115] The term "tautomer" refers to a functional group isomer resulting from the rapid movement of an atom between two positions within a molecule. The compounds disclosed herein can exhibit tautomerism. Tautomers can exist in two or more interconvertible forms. Tautomers generally exist in equilibrium, and attempts to isolate a single tautomer typically yield a mixture whose physicochemical properties are consistent with those of the mixture of compounds. The equilibrium position depends on the intramolecular chemical characteristics. For example, in many aliphatic aldehydes and ketones such as acetaldehyde, the ketone form is dominant; while in phenols, the enol form is dominant. This disclosure encompasses all tautomeric forms of the compounds.
[0116] The term "stereoisomer" refers to isomers that are produced by different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers and diastereomers.
[0117] The compounds disclosed herein may have asymmetric atoms such as carbon, sulfur, nitrogen, and phosphorus atoms, or asymmetric double bonds, and therefore may exist in specific geometric or stereoisomeric forms. Specific geometric or stereoisomeric forms may be cis and trans isomers, E- and Z-type geometric isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)- isomers, (L)- isomers, and racemic mixtures thereof or other mixtures, such as mixtures enriched with enantiomers or diastereomers. All such isomers and mixtures thereof are within the scope of the definition of the compounds disclosed herein. Alkyl groups or other substituents may contain additional asymmetric carbon atoms, asymmetric sulfur atoms, asymmetric nitrogen atoms, or asymmetric phosphorus atoms. All such isomers involved in all substituents, and mixtures thereof, are also included within the scope of the definition of the compounds disclosed herein. The compounds containing asymmetric atoms disclosed herein can be isolated in optically active pure form or in racemic form. The optically active pure form can be separated from racemic mixtures or synthesized using chiral starting materials or chiral reagents.
[0118] The term "substituted" refers to the substitution of one or more hydrogen atoms on a specific atom by a substituent, provided that the valence state of the specific atom is normal and the resulting compound is stable. When the substituent is oxo (i.e., =O), it means that two hydrogen atoms are substituted.
[0119] The terms “optional” or “optionally” mean that the event or condition subsequently described may or may not occur, including both the occurrence and non-occurrence of said event or condition. For example, “optionally” substituted with a halogen means that the ethyl group can be unsubstituted (CH2CH3), monosubstituted (CH2CH2F, CH2CH2Cl, etc.), polysubstituted (CHFCH2F, CH2CHF2, CHFCH2Cl, CH2CHCl2, etc.), or fully substituted (CF2CF3, CF2CCl3, CCl2CCl3, etc.). Those skilled in the art will understand that for any group containing one or more substituents, no substitution or substitution pattern that is spatially impossible and / or cannot be synthesized is introduced.
[0120] When any variable (e.g., R) a R b When a group appears more than once in the composition or structure of a compound, its definition is independent in each case. For example, if a group is surrounded by two R... b Replaced, then each R b Each has its own independent options.
[0121] When one of the variables is selected as a chemical bond or does not exist, it means that the two groups it is connected to are directly connected. For example, when L in ALZ represents a bond, it means that the structure is actually AZ.
[0122] If the linking group mentioned in this article does not specify its linking direction, then its linking direction is arbitrary. For example, when the structural unit... L in 1 When selected from "C1-C3 alkylene-O", L 1 Both loops Q and R can be connected in a left-to-right direction. 1 Composed of "cyclo-Q-C1-C3 alkylene-OR" 1 Alternatively, rings Q and R can be connected from right to left. 1 Composed of "cyclo-QO-C1-C3 alkylene-R" 1 ".
[0123] C in this article m -C n It refers to having an integer number of carbon atoms in the range mn. For example, "C1-C 10"" means that the group can have 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms.
[0124] The term "alkyl" refers to a compound with the general formula C1. n H 2n+1 The alkyl group can be straight-chain or branched. The term "C1-C" refers to a hydrocarbon group. 10 "Alkyl" can be understood as representing a straight-chain or branched saturated hydrocarbon group having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. Specific examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1 3-Dimethylbutyl or 1,2-Dimethylbutyl, etc.; the term "C1-C6 alkyl" can be understood as referring to alkyl groups having 1, 2, 3, 4, 5, or 6 carbon atoms, specific examples including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, hexyl, 2-methylpentyl, etc. The term "C1-C4 alkyl" can be understood as referring to straight-chain or branched saturated alkyl groups having 1, 2, 3, or 4 carbon atoms. The term "C1-C3 alkyl" can be understood as referring to straight-chain or branched saturated alkyl groups having 1, 2, or 3 carbon atoms. The "C1-C6 alkyl" 10 "alkyl" can include the range of "C1-C8 alkyl", "C1-C6 alkyl" or "C1-C3 alkyl", and the "C1-C6 alkyl" can further include "C1-C3 alkyl".
[0125] The term "halogenated alkyl" refers to a group formed by replacing one or more hydrogen atoms on an alkyl group with a halogen.
[0126] The term "alkoxy" refers to a group formed by the loss of a hydrogen atom from a hydroxyl group in straight-chain or branched alcohols; it can be understood as "alkyloxy" or "alkyl-O-". The term "C1-C"... 10 "Alkoxy" can be understood as "C1-C 10 "alkyloxy" or "C1-C" 10 Alkyl-O-"; the term "C1-C6 alkoxy" can be understood as "C1-C6 alkyloxy" or "C1-C6 alkyl-O-". The "C1-C" 10"Alkoxy" can include the range of "C1-C6 alkoxy" and "C1-C3 alkoxy", and the "C1-C6 alkoxy" can further include "C1-C3 alkoxy".
[0127] The term "alkenyl" refers to an unsaturated aliphatic hydrocarbon group consisting of a straight or branched chain of carbon and hydrogen atoms and having at least one double bond. The term "C2-C"... 10 "Alkenyl" can be understood as representing a straight-chain or branched unsaturated hydrocarbon group containing one or more double bonds and having 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms, "C2-C". 10 The term "alkenyl" may include "C2-C8 alkenyl," preferably "C2-C6 alkenyl," further preferably "C2-C4 alkenyl," and even more preferably C2 or C3 alkenyl. It is understood that when the alkenyl group contains more than one double bond, the double bonds may be separable or conjugated. Specific examples of the alkenyl group include, but are not limited to, vinyl, allyl, (E)-2-methylvinyl, (Z)-2-methylvinyl, (E)-but-2-enyl, (Z)-but-2-enyl, (E)-but-1-enyl, (Z)-but-1-enyl, isopropenyl, 2-methylprop-2-enyl, 1-methylprop-2-enyl, 2-methylprop-1-enyl, (E)-1-methylprop-1-enyl, or (Z)-1-methylprop-1-enyl, etc.
[0128] The term "cycloalkyl" refers to a fully saturated carbon ring existing in the form of a monocyclic, fused, bridged, or spirocyclic ring. Unless otherwise indicated, the carbon ring is typically a 3- to 10-membered ring. The term "C3-C" is also used. 10 "Cycloalkyl" can be understood as referring to a saturated monocyclic, fused, spirocyclic, or bridged ring having 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. Specific examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, norbornyl (bicyclo[2.2.1]heptyl), bicyclo[2.2.2]octyl, adamantyl, spiro[4.5]decyl, etc. The term "C3-C6 cycloalkyl" can be understood as referring to a saturated monocyclic, fused, spirocyclic, or bridged ring having 3, 4, 5, or 6 carbon atoms. Specific examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, etc. The term "C3-C4 cycloalkyl" can be understood as referring to a saturated monocyclic, fused, spirocyclic, or bridged ring having 3 or 4 carbon atoms. The term "C3-C6 cycloalkyl" can be understood as referring to a saturated monocyclic, fused, spirocyclic, or bridged ring having 3 or 4 carbon atoms. 10 "Cycloalkyl" can include "C3-C8 cycloalkyl" and "C3-C6 cycloalkyl".
[0129] The term "cycloalkenyl" refers to an incompletely saturated non-aromatic carbon ring existing in the form of a monocyclic, fused, bridged, or spirocyclic ring. Unless otherwise indicated, this carbon ring is typically a 5- to 10-membered ring. The term "C5-C" is also used.10 "Cycloalkenyl" can be understood as referring to a non-aromatic carbon ring that is not fully saturated and exists in the form of a monocyclic, fused, bridged, or spirocyclic ring, having 5, 6, 7, 8, 9, or 10 carbon atoms. Specific examples of cycloalkenyl include, but are not limited to, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, or cycloheptadienyl. The term "C5-C8 cycloalkenyl" can be understood as referring to a non-aromatic carbon ring that is not fully saturated and exists in the form of a monocyclic, fused, bridged, or spirocyclic ring, having 5, 6, 7, or 8 carbon atoms. The term "C5-C6 cycloalkenyl" can be understood as referring to a non-aromatic carbon ring that is not fully saturated and exists in the form of a monocyclic, fused, bridged, or spirocyclic ring, having 5 or 6 carbon atoms. 10 "Cycloalkenyl" can include "C5-C8 cycloalkenyl" and "C5-C6 cycloalkenyl".
[0130] The term "heterocyclic group" refers to a fully saturated or partially saturated monocyclic, fused, spirocyclic, or bridged ring group containing 1-5 heteroatoms or heterogroups (i.e., groups containing heteroatoms). These "heteroatoms or heterogroups" include, but are not limited to, nitrogen (N), oxygen (O), sulfur (S), phosphorus (P), boron (B), -S(=O)2-, -S(=O)-, -P(=O)2-, -P(=O)-, -NH-, -S(=O)(=NH)-, -C(=O)NH-, or -NHC(=O)NH-, etc. The term "4-18 membered heterocyclic group" refers to a heterocyclic group with 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 membered ring atoms, and its ring atoms contain 1-5 heteroatoms or heterogroups independently selected from those described above. The term "4-12 membered heterocyclic group" refers to a heterocyclic group with 4, 5, 6, 7, 8, 9, 10, 11, or 12 ring atoms, and whose ring atoms contain 1-5 independently selected heteroatoms or heteroatomic groups as described above. "4-10 membered heterocyclic group" includes "4-7 membered heterocyclic group", wherein specific examples of 4 membered heterocyclic groups include, but are not limited to, azirrocyclobutane or oxacyclobutane; specific examples of 5 membered heterocyclic groups include, but are not limited to, tetrahydrofuranyl, dioxacyclopentenyl, pyrrolyl, imidazoalkyl, pyrazolyl, pyrrolinyl, 4,5-dihydrooxazolyl, or 2,5-dihydro-1H-pyrrolyl; specific examples of 6 membered heterocyclic groups include, but are not limited to, tetrahydropyranyl, piperidinyl, morpholinyl, dithiaalkyl, thiomorpholinyl, piperazine, trithiaalkyl, tetrahydropyridinyl, or 4H-[1,3,4]thiadiazinyl; and specific examples of 7 membered heterocyclic groups include, but are not limited to, diazacycloheptane. The heterocyclic group can also be a bicyclic group, wherein specific examples of 5,5-membered bicyclic groups include, but are not limited to, hexahydrocyclopentano[c]pyrrolo-2(1H)-yl; specific examples of 5,6-membered bicyclic groups include, but are not limited to, hexahydropyrrolo[1,2-a]pyrazinolo-2(1H)-yl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, or 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazinyl. Optionally, the heterocyclic group can be a benzofused cyclic group or a heteroaromatic fused cyclic group of the above-mentioned 4-7-membered heterocyclic groups, specific examples of which include, but are not limited to, dihydroisoquinolinyl, etc. The heterocyclic group can also be a tricyclic group. "4-10 membered heterocyclic group" can include the ranges of "5-10 membered heterocyclic group", "4-7 membered heterocyclic group", "5-6 membered heterocyclic group", "6-8 membered heterocyclic group", "4-10 membered heterocyclic alkyl group", "5-10 membered heterocyclic alkyl group", "4-7 membered heterocyclic alkyl group", "5-6 membered heterocyclic alkyl group", and "6-8 membered heterocyclic alkyl group". "4-7 membered heterocyclic group" can further include the ranges of "4-6 membered heterocyclic group", "5-6 membered heterocyclic group", "4-7 membered heterocyclic alkyl group", "4-6 membered heterocyclic alkyl group", and "5-6 membered heterocyclic alkyl group".Although some bicyclic heterocyclic groups in this disclosure partially contain a benzene ring or a heteroaromatic ring, the heterocyclic group as a whole is still non-aromatic.
[0131] The term "aryl" refers to an aromatic ring group consisting of an all-carbon monocyclic or fused polycyclic aromatic cyclic group with a conjugated π-electron system. Aryl groups can have 6-20, 6-14, or 6-12 carbon atoms. The term "C6-C"... 20 "Aryl" can be understood as an aryl group having 6 to 20 carbon atoms. Specifically, it refers to a ring with 6 carbon atoms ("C6 aryl"), such as phenyl; or a ring with 9 carbon atoms ("C9 aryl"), such as indenyl or indenyl; or a ring with 10 carbon atoms ("C9 aryl"). 10 Aryl groups, such as tetrahydronaphthyl, dihydronaphthyl, or naphthyl; or rings having 13 carbon atoms (“C”). 13 Aryl groups, such as fluorene groups; or rings with 14 carbon atoms (“C”). 14 Aryl), for example, anthracene. The term "C6-C" is used. 10 "Aryl" can be understood as an aryl group having 6 to 10 carbon atoms. Specifically, it refers to a ring with 6 carbon atoms ("C6 aryl"), such as phenyl; or a ring with 9 carbon atoms ("C9 aryl"), such as indenyl or indenyl; or a ring with 10 carbon atoms ("C9 aryl"). 10 Aryl), such as tetrahydronaphthyl, dihydronaphthyl or naphthyl.
[0132] The term "heteroaryl" refers to an aromatic monocyclic or fused polycyclic system containing at least one ring atom selected from N, O, or S, with the remaining ring atoms being C. The term "5-10-membered heteroaryl" can be understood to include monocyclic or bicyclic aromatic ring systems having 5, 6, 7, 8, 9, or 10 ring atoms, particularly 5, 6, 9, or 10 ring atoms, and containing 1-5, preferably 1-3, heteroatoms independently selected from N, O, and S. Specifically, the heteroaryl group is selected from thienyl, furanyl, pyrroleyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl or thiadiazolyl and their benzo[derivatives], such as benzofuranyl, benzothienyl, benzothiazolyl, benzooxazolyl, benzoisooxazolyl, benzoimidazolyl, benzotriazolyl, indazole, indolyl or isindolyl; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl and their benzo[derivatives], such as quinolinyl, quinazolinyl or isoquinolinyl; or acrylinyl, inazinyl, purinyl and their benzo[derivatives]; or cyclolinyl, phthalazinyl, quinazolinyl, quinoxolinyl, naphthidyl, pteridinyl, carbazolyl, acrylinyl, phenazinyl, phenothiazinyl or phenothiazinyl. "5-10-membered heteroaryl" includes "5-6-membered heteroaryl". The term "5-6-membered heteroaryl" refers to an aromatic ring system having 5 or 6 ring atoms, and it contains 1 to 3, preferably 1 to 2, heteroatoms independently selected from N, O and S.
[0133] The term "leaving group" refers to a functional group or atom that can be replaced by another functional group or atom through a substitution reaction (e.g., nucleophilic substitution). For example, representative leaving groups include, but are not limited to, trifluoromethanesulfonates, chlorine, bromine, iodine, sulfonate groups (e.g., methanesulfonates, toluenesulfonates, p-bromobenzenesulfonates, p-toluenesulfonates), or acyloxy groups (e.g., acetoxy, trifluoroacetoxy).
[0134] The term "halogen" or "halogen" refers to fluorine, chlorine, bromine, or iodine.
[0135] The term "hydroxyl group" refers to the -OH group.
[0136] The term "amino" refers to the -NH2 group.
[0137] The term "WRN inhibitor" or "WRN helicase inhibitor" refers to a compound that inhibits Werner Syndrome RecQ DNA helicase (WRN). The term "WRN" refers to the protein of Werner Syndrome RecQ DNA helicase. The term "WRN" includes mutants, fragments, variants, subtypes, and homologues of full-length wild-type WRN. "WRN-mediated diseases or conditions" includes diseases or conditions treated by WRN inhibition, such as cancer.
[0138] The term "therapeutic effective amount" means (i) the amount of the disclosed compound used to treat a particular disease, condition, or disorder, or (ii) to reduce, improve, or eliminate one or more symptoms of a particular disease, condition, or disorder. The amount of the disclosed compound constituting a "therapeutic effective amount" varies depending on the compound, the disease state and its severity, the route of administration, and the age of the mammal to be treated, but may routinely be determined by someone skilled in the art based on their own knowledge and the content of this disclosure.
[0139] The term "pharmaceutical acceptable" refers to compounds, materials, compositions, and / or dosage forms that, within the bounds of reliable medical judgment, are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio.
[0140] The term "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable salt of an acid or base, including salts formed by a compound with an inorganic or organic acid, and salts formed by a compound with an inorganic or organic base.
[0141] The term "pharmaceutical composition" refers to a mixture of one or more compounds of the present disclosure or salts thereof with pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate the administration of the disclosed compounds to an organism.
[0142] The term "pharmaceuticalally acceptable excipient" refers to excipients that do not cause significant irritation to the organism and do not impair the biological activity and properties of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc.
[0143] The word “comprise” or “include” and its English variants such as comprises or comprising can be understood as having an open, non-exclusive meaning, that is, “including but not limited to”.
[0144] This disclosure also includes compounds of this disclosure that are identical to those described herein, but in which one or more atoms are labeled with isotopes whose atomic weights or mass numbers differ from those commonly found in nature. Examples of isotopes that can be incorporated into compounds of this disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as... 2 H, 3 H, 11 C 13 C 14 C 13 N、 15 N、15 O、 17 O、 18 O、 31 P, 32 P, 35 S, 18 F, 123 I, 125 I and 36 Cl, etc.
[0145] Certain isotope-labeled compounds of this disclosure (e.g., using...) 3 H and 14 C-labeling can be used in the analysis of compound and / or substrate tissue distribution. Tritiumization (i.e., 3 H) and carbon-14 (i.e. 14 C) Isotopes are particularly preferred due to their ease of preparation and detectability. Positron-emitting isotopes, such as... 15 O、 13 N、 11 C and 18 F can be used in positron emission tomography (PET) studies to determine substrate occupancy. The isotopically labeled compounds of this disclosure can typically be prepared by replacing the unlabeled reagent with an isotopically labeled reagent using a procedure similar to those disclosed in the schemes and / or examples below.
[0146] The pharmaceutical compositions disclosed herein can be prepared by combining the compounds disclosed herein with suitable pharmaceutically acceptable excipients, for example, in solid, semi-solid, liquid or gaseous formulations, such as tablets, pills, capsules, powders, granules, ointments, emulsions, suspensions, suppositories, injections, inhalers, gels, microspheres and aerosols.
[0147] Typical routes of administration of the disclosed compounds or their pharmaceutically acceptable salts or pharmaceutical compositions thereof include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, vaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, and intravenous administration.
[0148] The pharmaceutical compositions disclosed herein can be manufactured using methods well known in the art, such as conventional mixing, dissolving, granulation, emulsification, freeze drying, etc.
[0149] In some embodiments, the pharmaceutical composition is in an oral form. For oral administration, the pharmaceutical composition can be formulated by mixing the active compound with pharmaceutically acceptable excipients well known in the art. These excipients enable the compounds of this disclosure to be formulated into tablets, pills, lozenges, sugar-coated tablets, capsules, liquids, gels, pastes, suspensions, etc., for oral administration to patients.
[0150] Solid oral compositions can be prepared using conventional mixing, filling, or tableting methods. For example, they can be obtained by mixing the active compound with solid excipients, optionally milling the resulting mixture, adding other suitable excipients if necessary, and then processing the mixture into granules to obtain the core of a tablet or sugar-coated formulation. Suitable excipients include, but are not limited to, binders, diluents, disintegrants, lubricants, flow aids, or flavoring agents.
[0151] The pharmaceutical composition may also be suitable for parenteral administration, such as in suitable unit dosage forms of sterile solutions, suspensions or lyophilized products.
[0152] In all methods of administration of the compound of general formula I described herein, the daily dose may be from 0.01 mg / kg to 100 mg / kg body weight, in the form of single or separate doses.
[0153] The compounds disclosed herein can be prepared by a variety of synthetic methods known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthetic methods, and equivalent substitutions known to those skilled in the art. Preferred embodiments include, but are not limited to, the embodiments disclosed herein.
[0154] The chemical reactions in the specific embodiments of this disclosure are carried out in a suitable solvent, which must be suitable for the chemical changes of this disclosure and the reagents and materials required therefor. In order to obtain the compounds of this disclosure, it is sometimes necessary for those skilled in the art to modify or select the synthesis steps or reaction flow based on existing embodiments.
[0155] An important consideration in synthetic route planning in this field is the selection of appropriate protecting groups for reactive functional groups. For example, see Greene's Protective Groups in Organic Synthesis (4th Ed). Hoboken, New Jersey: John Wiley & Sons, Inc. All references cited in this disclosure are incorporated herein by reference in their entirety.
[0156] The following abbreviations are used in this disclosure:
[0157] Detailed Implementation
[0158] The invention is described in detail below with reference to embodiments, but this does not imply any adverse limitation of the present disclosure. The present disclosure has been described in detail, including specific embodiments thereof. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present disclosure without departing from the spirit and scope thereof. All reagents used in this disclosure are commercially available and can be used without further purification.
[0159] Unless otherwise stated, the proportions expressed for mixed solvents are volume-based.
[0160] Compounds are processed manually or Software naming conventions are used; commercially available compounds use supplier catalog names.
[0161] The structure of the compound was determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts are measured in units of 10⁻⁶. -6 (ppm). The solvents used for NMR determination were deuterated dimethyl sulfoxide, deuterated chloroform, deuterated methanol, etc., with tetramethylsilane (TMS) as the internal standard; "IC 50 "Half-inhibition concentration" refers to the concentration at which half of the maximum inhibitory effect is achieved.
[0162] The eluent described below may be a mixture of two or more solvents, with the ratio being the volume ratio of each solvent.
[0163] Example 1: Synthesis of (E)-2-(tert-butyl)-N-(3-(methanesulfonyl)-1-(oxecyclobutane-3-yl)allyl)-4-phenoxypyrimidine-5-carboxamide (Compound 1)
[0164]
[0165] Step 1: Synthesis of compound 1c
[0166] Compound 1a (1.0 g, 11.6 mmol) was dissolved in dry DCM (10 mL). Then, compound 1b (1.7 g, 13.9 mmol) and tetraisopropyl titanate (4.6 g, 16.3 mmol) were added. The resulting reaction mixture was stirred overnight at room temperature. The crude product was concentrated and purified by silica gel column chromatography (EA / PE = 0%–50%) to give compound 1c (1.6 g).
[0167] Step 2: Synthesis of compound 1e
[0168] Compound 1c (1.6 g, 8.45 mmol) was dissolved in dry DCM (30 mL). The solution was cooled to -60°C, and then compound 1d (1 M THF solution, 25 mL) was added dropwise. After the addition was complete, the reaction mixture was allowed to react completely at room temperature. The reaction was quenched with water (30 mL). The mixture was filtered through diatomaceous earth, and the filter cake was washed with DCM. The organic layer was separated, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The crude product was concentrated and purified by silica gel column chromatography (EA / PE = 45%) to give compound 1e (1.6 g).
[0169] Step 3: Synthesis of compound 1f
[0170] Compound 1e (1.5 g, 6.9 mmol) was dissolved in tetrahydrofuran (15 mL), followed by the addition of 5 mL of water, sodium carbonate (732 mg, 6.9 mmol), and iodine (876 mg, 3.45 mmol). The resulting reaction mixture was stirred at 50°C until fully incorporated. The reaction mixture was then cooled to room temperature, and saturated sodium thiosulfate solution (10 mL) and ethyl acetate (10 mL) were added. The organic layer was separated, washed with saturated sodium bicarbonate aqueous solution (20 mL) and saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and evaporated to dryness to obtain compound 1f (0.8 g, crude product). The crude product was used directly in subsequent reactions.
[0171] Step 4: Synthesis of Compound 1i
[0172] Compound 1 g (12.5 g, 124.80 mmol) and compound 1 h (27 g, 133.5 mmol) were dissolved in ethanol (150 mL) and cooled to 0°C. Sodium ethoxide (25.5 g, 374 mmol) was then added. The resulting reaction mixture was allowed to react completely at 90°C. After cooling to room temperature, ice water (200 mL) was added, and the mixture was extracted with ethyl acetate (2 × 150 mL). The combined organic layers were washed with saturated brine (100 mL), dried, filtered, and concentrated to give compound 1 i (14.2 g, crude product). The crude product was used directly in the next step.
[0173] Step 5: Synthesis of Compound 1j
[0174] Compound 1i (12.5 g, 55.7 mmol) was dissolved in phosphorus oxychloride (70 mL). The resulting mixture was reacted thoroughly at 80°C. The volatiles were removed under reduced pressure to obtain compound 1j (24 g, crude product). The crude product was used directly in the next step.
[0175] Step Six: Synthesis of Compound 1l
[0176] Compound 1j (10 g, crude) and phenol 1k (2.33 g, 24.7 mmol) were dissolved in ACN (70 mL). Potassium carbonate (8.54 g, 61.8 mmol) was then added. The resulting reaction mixture was stirred at 80 °C until fully reacted. The mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (EA / PE = 0%–50%) to give compound 1l (3.0 g).
[0177] Step 7: Synthesis of Compound 1m
[0178] Compound 1L (3.0 g, 10 mmol) was dissolved in THF (30 mL) and water (8 mL). Lithium hydroxide (598 mg, 25 mmol) was then added. The resulting reaction mixture was stirred thoroughly at room temperature. The solution was diluted with water (20 mL) and the pH was adjusted to 2-3 with 1 N hydrochloric acid. Extraction was performed with ethyl acetate (20 mL x 3), the combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 1M (2.8 g, crude). The crude product was used directly in the next step.
[0179] Step 8: Synthesis of compound 1n
[0180] Compound 1m (800 mg, 2.94 mmol) and compound 1f (800 mg, 7.08 mmol) were dissolved in DMF (15 mL). Then, HATU (1.33 g, 3.53 mmol) and triethylamine (0.6 g, 6 mmol) were added. The resulting solution was allowed to react completely at room temperature. Ethyl acetate (30 mL) and saturated ammonium chloride solution (30 mL) were added. The organic layer was separated, washed with saturated brine (30 mL x 2), and concentrated. The crude product was purified by silica gel column chromatography (EA / PE = 0%–45%) to give compound 1n (0.3 g).
[0181] Step Nine: Synthesis of Compound 1o
[0182] Intermediate 1n (130 mg, 354 μmol) and N-methylmorpholine oxide (124 mg, 1.1 mmol) were dissolved in THF (4 mL) and water (1 mL), followed by the addition of potassium osmium tetroxide dihydrate (2.6 mg, 7.1 μmol), and the reaction was allowed to proceed fully at room temperature. Sodium periodate (140 mg, 653 μmol) was then added, and the reaction was allowed to proceed fully at room temperature. Ethyl acetate (20 mL) and water (20 mL) were added, the mixture was separated, the organic phase was washed with saturated brine (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to dryness to give compound 1o (120 mg, crude product).
[0183] Step 10: Synthesis of Compound 1
[0184] Compound 1o (100 mg, 271 μmol), compound 1p (125 mg, 542 μmol), diisopropylethylamine (105 mg, 812 μmol), and lithium chloride (11.5 mg, 271 μmol) were mixed in anhydrous THF (2 mL) and reacted at room temperature. The reaction was quenched with water (10 mL), extracted with ethyl acetate (10 mL x 3), and the combined organic phases were washed once with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, concentrated to dryness under reduced pressure, and the residue was purified by reversed-phase rapid chromatography (C18 column, acetonitrile / water = 5%–70%) to give compound 1 (40 mg). LC-MS: m / z (ESI): 446.3 [M+H] + .
[0185] 1 H-NMR (400MHz, DMSO-d6) δ8.88-8.78(m,2H),7.52-7.42(m,2H),7.33-7.24(m,3H),6.92(dd,J=1 5.3,1.6Hz,1H),6.74(dd,J=15.3,4.8Hz,1H),5.16(tdd,J=8.6,4.9,1.6Hz,1H),4.63(ddd,J=19 6, 7.9, 6.3 Hz, 2H), 4.44 (dt, J = 18.5, 6.2 Hz, 2H), 3.28 (dd, J = 8.3, 6.1 Hz, 1H), 2.97 (s, 3H), 1.18 (s, 9H). Example 2: Synthesis of (E)-N-(1-(1-acetylazetane-3-yl)-3-(methanesulfonyl)allyl)-2-(tert-butyl)-4-phenoxypyrimidine-5-carboxamide (compound 2).
[0186]
[0187] Step 1: Synthesis of compound 2c
[0188] DBU (768 mg, 5.05 mmol, 753 μL) and compound 2b (4.14 g, 20.2 mmol) were added sequentially to a dichloromethane (4 mL) solution of compound 2a (1.5 g, 5.05 mmol) under ice bath conditions. The mixture was stirred at room temperature until fully reacted. The reaction solution was directly purified by column chromatography (EA / PE = 0-50%) to give compound 2c (1.6 g).
[0189] LC-MS: m / z (ESI): 399.1 [M+Na] +
[0190] Step 2: Synthesis of compound 2d
[0191] To a 10 mL solution of compound 2c (1.6 g, 4.25 mmol) in tetrahydrofuran, 50 mg of wet palladium on carbon was added, and hydrogen gas was displaced. The mixture was stirred at room temperature until fully reacted. The reaction solution was filtered to remove the palladium on carbon and then evaporated to dryness to give compound 2d (1 g).
[0192] LC-MS: m / z (ESI): 189.1 [M-56+H] +
[0193] Step 3: Synthesis of compound 2e
[0194] To a solution of compound 2d (500 mg, 2.05 mmol) in dichloromethane (5 mL), DIEA (661 mg, 5.12 mmol, 891 μL) and acetic anhydride (250 mg, 2.46 mmol, 232 μL) were added sequentially. The reaction mixture was stirred at room temperature until fully soluble. The mixture was then subjected to direct column chromatography (EA / PE = 0-80%) to give compound 2e (466 mg).
[0195] LC-MS: m / z (ESI): 231.1 [M-56+H] +
[0196] Step 4: Synthesis of compound 2f
[0197] Add a solution of 1,4-dioxane hydrochloric acid (4M, 1 mL) to a methanol (1 mL) solution of compound 2e (350 mg, 1.22 mmol). Stir at room temperature until fully reacted. Reduce the solution to dryness to obtain compound 2f (hydrochloride, 270 mg), which can be used directly in the next step.
[0198] LC-MS: m / z (ESI): 187.1 [M+H] +
[0199] Step 5: Synthesis of 2g of compound
[0200] To a DMF (3 mL) solution of compound 1m (94.2 mg, 345.8 μmol), DIEA (134.1 mg, 1.04 mmol, 180.7 μL), HATU (156.6 mg, 415.0 μmol), and compound 2f (hydrochloride, 77 mg, 345.8 μmol) were added sequentially. The reaction mixture was stirred at room temperature until fully soluble. The mixture was then subjected to direct column chromatography (MeOH / DCM = 0-6%) to give 2 g (150 mg) of compound. LC-MS: m / z (ESI): 441.1 [M+H] +
[0201] Step Six: Synthesis of Compound 2h
[0202] Lithium aluminum hydride (1M, 163.5 μL, 136.2 μmol) was added to a 2 g (60 mg, 136.2 μmol) solution of the compound in 1.5 mL of tetrahydrofuran at -20 °C in an ice-salt bath. The reaction mixture was stirred thoroughly at this temperature. The reaction was quenched with water (10 mL) and extracted with ethyl acetate (10 mL). The organic phase was evaporated to dryness to give compound 2h (40 mg). This compound was used directly in the next reaction.
[0203] LC-MS: m / z (ESI): 413.2 [M+H] +
[0204] Step 7: Synthesis of Compound 2i
[0205] Under ice bath conditions, sodium bicarbonate (24.4 mg, 290 μmol) and Dysmart reagent (82.3 mg, 194 μmol) were added to a 2 mL solution of compound 2h (40 mg, 97.0 μmol) in dichloromethane. The reaction mixture was stirred at room temperature until fully incorporated. The solution was diluted with 10 mL of ethyl acetate and washed with 10 mL of saturated sodium bicarbonate aqueous solution. The organic phase was evaporated to dryness to give compound 2i (39 mg). LC-MS: m / z (ESI): 411.1 [M+H] + .
[0206] Step 8: Synthesis of Compound 2
[0207] To a 2 mL solution of compound 2i (40 mg, 97.5 μmol) in tetrahydrofuran, DIEA (37.8 mg, 292 μmol, 50.9 μL), compound 1p (24.7 mg, 107.2 μmol), and lithium chloride (4.13 mg, 97.5 μmol) were added sequentially. The mixture was stirred at room temperature until fully reacted. The mixture was purified by reversed-phase rapid chromatography (C18 column, MeCN / H2O = 58%) to give compound 2 (3 mg).
[0208] LC-MS: m / z (ESI): 487.10 [M+H] + .
[0209] 1H NMR (400MHz, CDCl3) δ9.25 (d, J=9.3Hz, 1H), 7.75 (dd, J=50.5, 8.3Hz, 1H), 7.45–7.37 (m, 2H ),7.31–7.25(m,1H),7.13–7.06(m,2H),6.77(dt,J=15.1,5.3Hz,1H),6.56(dt,J=15.1,2. 0Hz,1H),5.14(dq,J=31.2,7.4Hz,1H),4.17(dt,J=25.7,8.6Hz,1H),4.10–4.00(m,1H),3. 93–3.82(m,1H),3.79–3.71(m,1H),2.91–2.85(m,4H),1.65(d,J=54.5Hz,3H),1.15(s,9H).
[0210] Example 3: Synthesis of (E)-2-(1,1-difluoroethyl)-N-(3-(methanesulfonyl)-1-(oxetane-3-yl)allyl)-4-phenoxypyrimidine-5-carboxamide (Compound 3)
[0211]
[0212] Step 1: Synthesis of compound 3b
[0213] Potassium carbonate (18.8 g, 135 mmol) and compound 1k (8.52 g, 90.5 mmol) were added sequentially to a DMF (100 mL) solution of compound 3a (20 g, 90.5 mmol) at 0 °C. The mixture was stirred at room temperature until fully reacted. Water (400 mL) was added to the reaction solution, resulting in the precipitation of a large amount of solid. The mixture was filtered, and the filter cake was washed with a small amount of water. After drying, compound 3b (24.6 g) was obtained.
[0214] MSm / z(ESI): 279.00 [M+H] + .
[0215] Step 2: Synthesis of compound 3d
[0216] Compound 3c (7.96 g, 53.8 mmol), an aqueous solution of potassium carbonate (9.92 g, 71.8 mmol), and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (1.31 g, 1.79 mmol) were added sequentially to a solution of compound 3b (10 g, 35.9 mmol) in 1,4-dioxane (80 mL) at 25 °C. After purging with nitrogen, the mixture was stirred at 90 °C until fully reacted. A portion of the solvent was removed by rotary evaporation, and the solution was diluted with ethyl acetate (50 mL) and washed with saturated brine (80 mL). The organic phase was separated, evaporated to dryness, and subjected to silica gel column chromatography (EA / PE = 10%) to give compound 3d (4.3 g).
[0217] 1 H NMR(400MHz, CDCl3)δ9.04(s,1H),7.39–7.30(m,2H),7.22–7.17(m,1H),7.15–7.09(m,2H),6. 22–6.14(m,1H),5.43–5.37(m,1H),4.36(q,J=7.1Hz,2H),1.95(s,3H),1.34(t,J=7.1Hz,3H).
[0218] Step 3: Synthesis of compound 3e
[0219] Potassium osmium tetroxide dihydrate (21.0 mg, 57 μmol) was added to a mixed solution of compound 3d (5.4 g, 19.0 mmol) in THF (40 mL) and water (10 mL) at 25 °C. After stirring for 5 minutes, sodium periodate (10.6 g, 49.0 mmol) was added. The mixture was stirred at room temperature until fully precipitated, and a solid was formed. The reaction solution was diluted with water (50 mL) and extracted twice with ethyl acetate (50 mL). The combined organic phases were evaporated to dryness to give compound 3e (5.1 g). The crude product was used directly in the next step.
[0220] MSm / z(ESI): 287.10 [M+H] + .
[0221] Step 4: Synthesis of compound 3f
[0222] Bis(2-methoxyethyl)aminosulfur trifluoride (11.0 g, 49.9 mmol) was added dropwise to a solution of compound 3e (5.1 g, 17.8 mmol) in dichloroethane (50 mL) at room temperature. The mixture was stirred at 80 °C until fully reacted. After the reaction solution was cooled to 0 °C, water (80 mL) was slowly added dropwise to quench the reaction, and the mixture was extracted twice with dichloromethane (50 mL). The combined organic phases were evaporated to dryness and subjected to silica gel column chromatography (EA / PE = 10%) to give compound 3f (4.6 g).
[0223] MSm / z(ESI): 309.00 [M+H] + .
[0224] 1 H NMR (400MHz, CDCl3) δ9.19 (s, 1H), 7.46–7.40 (m, 2H), 7.29 (t, J = 7.4Hz, 1H), 7.21– 7.17(m,2H),4.46(q,J=7.1Hz,2H),1.83(t,J=18.6Hz,3H),1.42(t,J=7.1Hz,3H).
[0225] Step 5: Synthesis of 3g of compound
[0226] At room temperature, an aqueous solution (40 mL) of lithium hydroxide monohydrate (1.66 g, 39.6 mmol) was added dropwise to a THF (40 mL) solution of compound 3f (6.1 g, 19.8 mmol). The reaction mixture was stirred at 25 °C until fully reacted. After removing tetrahydrofuran from the reaction mixture, 2 M hydrochloric acid aqueous solution (30 mL) was slowly added dropwise, and a solid precipitated. The solid was extracted twice with ethyl acetate (40 mL). The combined organic phases were evaporated to dryness to give compound 3 g (5.4 g). The crude product was used directly in the next step.
[0227] MSm / z(ESI): 281.00 [M+H] + .
[0228] Step Six: Synthesis of Compound 3h
[0229] Compound 3 g (290 mg, 1.03 mmol) and compound 1f (117.1 mg, 1.03 mmol) were dissolved in DMF (5 mL). Then HATU (413.2 mg, 1.09 mmol) and DIEA (400.5 mg, 3.10 mmol) were added. The resulting reaction mixture was stirred at room temperature until fully incorporated. Then ethyl acetate (50 mL) and a saturated ammonium chloride aqueous solution (20 mL) were added. The organic layer was separated and washed with brine (20 mL). The solution was evaporated to dryness, and the crude product was separated by silica gel column chromatography (EA / PE = 40%) to give compound 3h (295 mg).
[0230] Step 7: Synthesis of Compound 3i
[0231] Compound 3h (295 mg, 785.9 μmol) was dissolved in THF (8 mL). Then, water (1.5 mL), N-methylmorpholine oxide (276.2 mg, 2.36 mmol), and potassium osmium tetroxide dihydrate (14.7 mg, 40 μmol) were added sequentially. The resulting reaction mixture was stirred thoroughly at room temperature. The reaction was then quenched with a 10% sodium thiosulfate aqueous solution (5 mL). Water (5 mL) and ethyl acetate (30 mL) were added. The organic layer was separated and washed with brine (20 mL). The solution was evaporated to dryness to give compound 3i (340 mg). The crude product was used directly in the next step.
[0232] Step 8: Synthesis of Compound 3j
[0233] Compound 3i (340 mg, 830.5 μmol) was dissolved in THF (6 mL). Water (1.2 mL) and sodium periodate (355 mg, 1.66 mmol) were then added. The resulting reaction mixture was stirred thoroughly at room temperature. The reaction was quenched with an aqueous solution of sodium thiosulfate (5 mL). Water (5 mL) and ethyl acetate (30 mL) were added. The organic layer was separated and washed with brine (20 mL). The mixture was evaporated to dryness to give compound 3j (330 mg). The crude product was used directly in the next step.
[0234] Step Nine: Synthesis of Compound 3
[0235] LiCl (37.1 mg, 874.5 μmol) and DIEA (338 mg, 2.62 mmol) were added to a THF (5 mL) solution of compound 3j (330 mg, 874.5 μmol) and compound 1p (302 mg, 1.31 mmol). The reaction mixture was allowed to react completely at room temperature. The reaction was quenched with water (10 mL), extracted with ethyl acetate (15 mL x 2), and the combined organic phases were washed once with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, concentrated to dryness under reduced pressure, and the residue was purified by reversed-phase chromatography (C18 column, acetonitrile / water = 5%–70%) to give compound 3 (175 mg).
[0236] LC-MS: m / z (ESI): 454.43 [M+H] + .
[0237] 1H NMR(400MHz, CDCl3)δ9.49(s,1H),8.13(d,J=7.8Hz,1H),7.54–7.45(m,2H),7.41–7.33(m,1H),7.25–7.20(m,2H),6.82(dd,J=15.1,5.2Hz,1H),6 .62(dd,J=15.1,1.5Hz,1H),5.29(q,J=6.9Hz,1H),4.97–4.82(m,2H),4. 56–4.39(m,2H),3.32–3.21(m,1H),2.96(s,3H),1.86(t,J=18.5Hz,3H).
[0238] Example 4: (E)-2-(tert-butyl)-N-(3-(methanesulfonyl)-1-(1-(2,2,2-trifluoroethyl)azacyclobutane-3-yl)allyl)-4-phenoxypyrimidine-5-carboxamide
[0239]
[0240] Step 1: Synthesis of compound 4b
[0241] Compound 4a (114 mg, 491 μmol) was added to a solution of compound 2d (100.0 mg, 409.4 μmol) and N,N-diisopropylethylamine (155 mg, 1.2 mmol) in acetonitrile (2 mL). The mixture was heated and stirred at 80 °C until fully reacted. After the reaction was complete, the reaction solution was poured into water (10 mL), extracted with ethyl acetate (10 mL x 3), the organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to dryness under reduced pressure to give compound 4b (119.0 mg). The crude product was used directly in the next reaction.
[0242] Step 2: Synthesis of compound 4c
[0243] p-Toluenesulfonic acid (189 mg, 1.1 mmol) was added to a solution of compound 4b (119 mg, 365 μmol) in acetonitrile (3.5 mL). The mixture was stirred at room temperature for 12 h until the reaction was complete. The reaction solution was then concentrated to dryness under reduced pressure to give compound 4c (82.0 mg). The crude product was used directly in the next reaction step.
[0244] Step 3: Synthesis of compound 4d
[0245] HATU (94 mg, 247 μmol) and N,N-diisopropylethylamine (106 mg, 824 μmol) were added to a solution of compound 4c (p-toluenesulfonate, 82.0 mg, 206 μmol) and 2-tert-butyl-4-phenoxypyrimidine-5-carboxylic acid 1m (56.1 mg, 206 μmol) in N,N-dimethylformamide (4 mL). The mixture was stirred at room temperature until fully reacted. The reaction solution was poured into water (10 mL), extracted with ethyl acetate (15 mL x 2), the organic phases were combined, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (PE / EA = 0-60%) to give compound 4d (170.0 mg).
[0246] Step 4: Synthesis of compound 4e
[0247] Diisobutylaluminum hydride (1.5M toluene solution, 708 μL, 1.1 mmol) was added to a THF solution of compound 4d (170 mg, 354 μmol) at -78 °C. The mixture was stirred at -78 °C until fully reacted. The reaction was then quenched by adding saturated ammonium chloride solution (10 mL), and the mixture was extracted with ethyl acetate (15 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to dryness under reduced pressure to give compound 4e (150.0 mg). The crude product was used directly in the next reaction.
[0248] Step 5: Synthesis of Compound 4
[0249] N,N-diisopropylethylamine (121 mg, 932 μmol) and lithium chloride (13.2 mg, 311 μmol) were added to a tetrahydrofuran (4 mL) solution of compound 4e (140 mg, 311 μmol) and compound 1p (85.9 mg, 373 μmol). The mixture was stirred at room temperature until fully reacted. After the reaction was complete, the reaction solution was poured into water (15 mL), extracted with ethyl acetate (15 mL × 2), the organic phases were combined, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by reversed-phase chromatography (C18 column, acetonitrile / water = 40%–75%) to give compound 4 (32.8 mg).
[0250] MSm / z(ESI): 527.2 [M+H] + .
[0251] 1H NMR(400MHz, DMSO-d6)δ8.85(s,1H),8.71(d,J=8.5Hz,1H),7.52–7.43(m,2H),7.33–7.25(m,3H),6.90(dd,J=15.3,1.5Hz,1H),6.76- 6.67(m,1H),5.04–4.94(m,1H),3.50–3.38(m,2H),3.27–3.16(m,2H),3.15–3.05(m,2H),2.98(s,3H),2.84–2.72(m,1H),1.18(s,9H).
[0252] Example 5: Synthesis of (E)-2-(cyclopropyldifluoromethyl)-N-(3-(methanesulfonyl)-1-(oxetane-3-yl)allyl)-4-phenoxypyrimidine-5-carboxamide (Compound 5)
[0253]
[0254] Step 1: Synthesis of compound 5b
[0255] Compound 3b (1.25 g, 4.5 mmol) was added to a 50 mL reaction flask, along with 1,4-dioxane (10 mL) and water (1 mL). The mixture was stirred under argon protection. Then, compound 5a (1.0 g, 5.2 mmol), potassium carbonate (1.9 g, 13.4 mmol), and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (328 mg, 448 μmol) were added sequentially to the system. The mixture was stirred at 85 °C until fully reacted. The mixture was diluted with ethyl acetate (150 mL), washed twice with water (30 mL × 2), washed twice with saturated brine (30 mL × 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was mixed with silica gel for column chromatography purification using gradient elution (0-25% EA / PE). The product was collected to give compound 5b (487 mg).
[0256] Step 2: Synthesis of compound 5c
[0257] Compound 5b (480 mg, 1.6 mmol) was added to a 50 mL reaction flask, along with anhydrous tetrahydrofuran (9 mL) and water (3 mL). The mixture was stirred, followed by the addition of potassium osmium hydrate (48.3 mg, 131 μmol). The mixture was stirred for 10 min, and then sodium periodate (992 mg, 4.64 mmol) was added. The mixture was stirred at room temperature until fully reacted. The mixture was diluted with ethyl acetate (100 mL), washed twice with water (20 mL × 2), twice with saturated brine (20 mL × 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to obtain compound 5c (480 mg). The crude product was used directly in the next reaction step.
[0258] Step 3: Synthesis of compound 5d
[0259] Compound 5c (480 mg, 1.54 mmol) was added to a 50 mL reaction flask, followed by the addition of dichloromethane (2 mL). The mixture was stirred, and then diethylaminosulfur trifluoride (3 mL) was added. The system was stirred at room temperature until fully reacted. The system was cooled in an ice bath, and then the reaction was quenched with saturated sodium bicarbonate solution (15 mL). Dichloromethane (60 mL) was added, and the mixture was allowed to separate into layers. The organic phase was washed once with water (20 mL) and once with saturated brine (20 mL). The organic phase was dried over anhydrous sodium sulfate, and the solvent was removed by concentration under reduced pressure. The residue was purified by silica gel column chromatography with gradient elution (0-40% EA / PE). The product was collected to give compound 5d (330 mg).
[0260] Step 4: Synthesis of compound 5e
[0261] Compound 5d (330 mg, 987 μmol) was added to a 25 mL reaction flask, followed by tetrahydrofuran (6 mL) and water (3 mL). The mixture was stirred, and then lithium hydroxide monohydrate (126 mg, 3.0 mmol) was added. The system was stirred at room temperature until fully reacted. The system was diluted with water (10 mL), and the pH was adjusted to 2-3. The mixture was then extracted three times with ethyl acetate (15 mL × 3). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to dryness to give compound 5e (300 mg). The crude product was used directly in the next reaction.
[0262] Step 5: Synthesis of compound 5f
[0263] Compound 5e (170 mg, 555 μmol) and compound 1f (62.8 mg, 555 μmol) were dissolved in DMF (5 mL). Then, HATU (222 mg, 583 μmol) and DIEA (216 mg, 1.67 mmol) were added. The system was stirred at room temperature until fully reacted. The system was diluted with ethyl acetate (50 mL), washed once with saturated ammonium chloride aqueous solution (20 mL), and once with saturated brine (20 mL). The solution was concentrated to dryness under reduced pressure. The residue was purified by silica gel column chromatography (PE / EA = 0-40%) to give compound 5f (200 mg).
[0264] Step Six: Synthesis of 5g of Compound
[0265] Compound 5f (200 mg, 498 μmol) was dissolved in tetrahydrofuran (8 mL). Then, water (1.5 mL), N-methylmorpholine-N-oxide (67.4 mg, 575 μmol), and potassium osmium hydrate (9.3 mg, 25.3 μmol) were added. The system was stirred at room temperature until fully induced. The reaction was quenched with 10% sodium thiosulfate aqueous solution (5 mL) and water (10 mL). The mixture was then extracted with ethyl acetate (50 mL), the organic layer was separated, washed with saturated brine (15 mL), and concentrated to dryness under reduced pressure to give 5 g (250 mg) of compound. The crude product was used directly in the next reaction step.
[0266] Step 7: Synthesis of Compound 5h
[0267] 5 g (250 mg, 574 μmol) of the compound was dissolved in tetrahydrofuran (8 mL). Then, water (1.5 mL) and sodium periodate (248 mg, 1.15 mmol) were added. The system was stirred at room temperature until fully induced. The reaction was quenched by adding 5 mL of 10% sodium thiosulfate aqueous solution and 10 mL of water. The mixture was then extracted with ethyl acetate (50 mL), the organic layer was separated, washed twice with saturated brine (10 × 2 mL), and concentrated to dryness under reduced pressure to give 5 h (220 mg) of compound. The crude product was used directly in the next reaction step.
[0268] Step 8: Synthesis of Compound 5
[0269] Compound 5h (220 mg, 545 μmol) was dissolved in THF (5 mL), followed by the addition of compound 1p (188 mg, 818 μmol), LiCl (23.1 mg, 545 μmol), and DIEA (211 mg, 1.64 mmol). The reaction mixture was stirred at room temperature until fully incorporated. The mixture was diluted with ethyl acetate (50 mL), washed once with saturated ammonium chloride aqueous solution (20 mL), and once with saturated brine (20 mL). The solution was concentrated to dryness under reduced pressure. The residue was purified by reversed-phase chromatography (C18 column, acetonitrile / water = 40%–70%) to give compound 5 (10.9 mg).
[0270] MSm / z(ESI): 480.43 [M+H] + .
[0271] 1 H NMR (400MHz, CDCl3) δ9.49 (s, 1H), 8.12 (d, J = 7.9Hz, 1H), 7.55–7.45 (m, 2H), 7.4 0–7.32(m,1H),7.24–7.17(m,2H),6.82(dd,J=15.1,5.2Hz,1H),6.62(dd,J=15. 1,1.6Hz,1H),5.40–5.22(m,1H),4.95–4.80(m,2H),4.54–4.39(m,2H),3.36–3. 22(m,1H),2.96(s,3H),1.56–1.46(m,1H),0.75–0.67(m,2H),0.63–0.48(m,2H).
[0272] Biological activity and related property test examples
[0273] The compounds in the following test examples were all prepared according to the methods described in the embodiments of this disclosure.
[0274] Test Example 1: Assay of WRN ATP hydrolase inhibitory activity
[0275] Experimental Principle
[0276] WRN unwinding is driven by the hydrolysis of ATP by the ATP-hydrolyzing domain in the WRN protein. ATP hydrolysis generates ADP, releasing energy to promote WRN unwinding. The ADP generated in the reaction is detected using the ADP-Glo assay kit (Promega). The signal value after adding the assay reagent is positively correlated with the amount of ADP generated in the reaction system; changes in the signal value reflect changes in the ATP-hydrolyzing activity of the WRN protein.
[0277] Experimental instruments
[0278] Instrument Name Equipment manufacturers model Nanoscale acoustic wave transfer system Labcyte Echo650 ELISA reader PerkinElmer Envision 2105
[0279] Experimental materials
[0280]
[0281] Experimental methods
[0282] The analyte was dissolved in DMSO, and the stock solution concentration was 10 mM. The stock solution was serially diluted using the Echo instrument's dose-response program with DMSO as the dilution solvent. The total experimental volume was 4 μL, starting at 10 μM, with 3-fold dilutions and 10 concentration points. The total volume of the compound and DMSO was 160 nL, and the final DMSO concentration was 0.4%. 2 μL of 2XWRN-ATP mixture (buffer: 25 mM Tris-HCl (pH 8.0), 50 mM NaCl, 2 mM MgCl2, 1 mM DTT, 0.01% Tween-20, 0.00025% BSA; WRN: 20 nM; ATP: 600 μM) was added to the experimental plate and incubated at room temperature for 3 hours. Then, 2 μL of 2XHecl (0.4 nM) was added and incubated at room temperature for 0.5 hours. Next, 4 μL of ADP-Glo reagent (ADP-Glo detection kit) was added and incubated for another 1 hour. Finally, 8 μL of Detection reagent (ADP-Glo detection kit) was added and incubated at room temperature for 1 hour. The chemiluminescence signal value was read on an Envision microscope. The signal value of the WRN reaction well was defined as the 0% inhibition control, and the signal value of the well without WRN was defined as the 100% inhibition control. The inhibition rate of the compound-treated wells was calculated. The IC50 was calculated using a four-parameter fitting method based on the inhibition rate. 50 .
[0283] The experimental results are shown in the table below:
[0284] Compound numbering <![CDATA[WRN ATP hydrolysis enzyme inhibitory activity IC 50 (nM)]]> Compound 1 190 Compound 2 612 Compound 3 745 Compound 4 659 Compound 5 410
[0285] The compounds disclosed in this embodiment exhibit good WRN ATP hydrolase inhibitory activity.
Claims
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof, in, R 3 Selected from 4-membered heterocyclic groups, 7-12-membered heterocyclic groups, C6-C 10 Aryl or 5-10 membered heteroaryl, wherein the 4-membered heterocyclic group, 7-12 membered heterocyclic group, C6-C 10 Aryl or 5-10 heteroaryl groups may be substituted; X is selected from N or CR x ; Y is selected from N or CR y ; Z is selected from N or CR. z ; Alternatively, Y and Z, together with their connected bonds, form a 5-6 membered heteroaromatic ring or a 5-6 membered heterocyclic ring, which may optionally be substituted. The condition is that X, Y, and Z are not all N at the same time; R x R y and R z Each is independently selected from H, halogen, cyano, amino, NHC(=O)C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, C1-C6 haloalkyl or C3-C6 cycloalkyl; L 1 Selected from bond, O, S, NR, CH2 or OCH2, wherein CH2 or OCH2 is optionally substituted with a halogen; R is selected from hydrogen, C1-C3 alkyl, or C1-C3 haloalkyl; R 1 Selected from C3-C8 cycloalkyl, C1-C6 alkyl, C6-C 10 aryl, 5-10 membered heteroaryl or 4-12 membered heterocyclic, wherein the C3-C8 cycloalkyl, C1-C6 alkyl, C6-C 10 Aryl, 5-10 membered heteroaryl, or 4-12 membered heterocyclic group may be substituted; R 2 Selected from C3-C8 cycloalkyl, C5-C 10 Cycloalkenyl, C6-C 10 Aryl, C1-C6 alkyl, amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, NH(C3-C8 cycloalkyl), N(C1-C6 alkyl)(C3-C8 cycloalkyl), C2-C6 alkenyl, -S-C1-C6 alkyl, C1-C6 alkoxy, -O-C3-C8 cycloalkyl, 4-12 membered heterocyclic or 5-10 membered heteroaryl, wherein the C3-C8 cycloalkyl, C5-C 10 Cycloalkenyl, C6-C 10 Aryl, C1-C6 alkyl, amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, NH(C3-C8 cycloalkyl), N(C1-C6 alkyl)(C3-C8 cycloalkyl), C2-C6 alkenyl, -S-C1-C6 alkyl, C1-C6 alkoxy, -O-C3-C8 cycloalkyl, 4-12 membered heterocyclic or 5-10 membered heteroaryl, may be optionally substituted; or R 2 Y and the carbon atoms they are attached to form C6-C. 10 Aromatic rings, C5-C 10 Cyclic olefin rings, 5-6 membered heteroaromatic rings, or 5-6 membered heterocycles, wherein the C6-C 10 Aromatic rings, C5-C 10 Cycloolefin rings, 5-6 membered heteroaromatic rings, or 5-6 membered heterocycles may be optionally substituted; L 2 Selected from -C(=O)NH-, -C(=S)NH-, -S(=O)2NH-, 1,2,3-triazolyl, oxadiazolyl, imidazolyl, tetrazolyl, pyrazolyl, -NHC(=O)NH-, -NHC(=O)O-, -CH(CF3)NH- or Q is selected from Q 1 Q 2 Q 3 Or Q 4 ; Q 1 yes in, represent It is either (Z) configuration or (E) configuration; X 3 Selected from O, NH or NR 5 ; R 4 Selected from C1-C6 alkyl, C3-C6 cycloalkyl or 4-6 membered heterocyclic groups, wherein the C1-C6 alkyl, C3-C6 cycloalkyl or 4-6 membered heterocyclic groups may optionally be substituted; R 5 Selected from cyano, C(=O)C1-C6 alkyl, C1-C6 alkyl, C3-C6 cycloalkyl, or 4-6 membered heterocyclic groups, wherein the C(=O)C1-C6 alkyl, C1-C6 alkyl, C3-C6 cycloalkyl, or 4-6 membered heterocyclic group may optionally be substituted; Q 2 yes in, represent It is either (Z) configuration or (E) configuration; Q 3 yes Q 4 yes Among them, R a It is a C1-C6 alkyl group, wherein the C1-C6 alkyl group may optionally be substituted.
2. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein, R 3 Selected from 4-membered heterocyclic groups, 7-12-membered heterocyclic groups, C6-C 10 Aryl or 5-10 membered heteroaryl, wherein the 4-membered heterocyclic group, 7-12 membered heterocyclic group, C6-C 10 Aryl or 5-10 heteroaryl groups are selectively coated with R. 3a Replace; or R 3 Selected from 4-membered heterocyclic groups, wherein the 4-membered heterocyclic group is optionally R 3a Replace; or R 3 Selected from oxetane or azirnebutane, wherein the oxetane or azirnebutane is optionally R 3a Replace; or R 3 Selected from or R 3 Selected from 3. The compound of formula (I) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein, R 3a Selected from halogen, cyano, hydroxy, amino, carboxyl, oxo, -S-C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, -S-C1-C6 alkyl, -O-C3-C6 cycloalkyl, C(=O)NH2, C(=O)NH(C1-C6 alkyl), C(=O)N(C1-C6 alkyl)2, phenoxy, C(=O)C1-C6 alkyl or S(O)2C1-C 6 alkyl groups, wherein the amino group, -S-C3-C8 cycloalkyl group, C1-C6 alkyl group, C1-C6 alkoxy group, C3-C6 cycloalkyl group, -S-C1-C6 alkyl group, -O-C3-C6 cycloalkyl group, C(=O)NH2, C(=O)NH(C1-C6 alkyl group), C(=O)N(C1-C6 alkyl group)2, phenoxy group, C(=O)C1-C6 alkyl group, or S(O)2C1-C6 alkyl group may optionally be substituted; or R 3a Selected from halogen, cyano, hydroxy, amino, carboxyl, oxo, -S-C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, -S-C1-C6 alkyl, -O-C3-C6 cycloalkyl, C(=O)NH2, C(=O)NH(C1-C6 alkyl), C(=O)N(C1-C6 alkyl)2, phenoxy, C(=O)C1-C6 alkyl or S(O)2C1 -C6 alkyl, wherein the amino group, -S-C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, -S-C1-C6 alkyl, -O-C3-C6 cycloalkyl, C(=O)NH2, C(=O)NH(C1-C6 alkyl), C(=O)N(C1-C6 alkyl)2, phenoxy, C(=O)C1-C6 alkyl or S(O)2C1-C6 alkyl is optionally R 3b Replace; or R 3a Selected from halogens, amino groups, C1-C6 alkyl groups, C1-C6 alkoxy groups, -S-C1-C6 alkyl groups, C(=O)NH2, C(=O)NH(C1-C6 alkyl), C(=O)N(C1-C6 alkyl)2, C(=O)C1-C6 alkyl, or S(O)2C1-C6 alkyl groups, wherein the amino group, C1-C6 alkyl group, C1-C6 alkoxy group, -S-C1-C6 alkyl group, C(=O)NH2, C(=O)NH(C1-C6 alkyl), C(=O)N(C1-C6 alkyl)2, C(=O)C1-C6 alkyl, or S(O)2C1-C6 alkyl group is optionally R 3b Replace; or R 3a Selected from C1-C6 alkyl, C(=O)C1-C6 alkyl, or S(O)2C1-C6 alkyl, wherein the C1-C6 alkyl, C(=O)C1-C6 alkyl, or S(O)2C1-C6 alkyl is optionally R 3b Replace; or R 3a Selected from C1-C3 alkyl, C(=O)C1-C3 alkyl, or S(O)2C1-C3 alkyl, wherein the C1-C3 alkyl, C(=O)C1-C3 alkyl, or S(O)2C1-C3 alkyl is optionally R 3b Replace; or R 3a Selected from methyl, ethyl, C(=O)CH3 or S(O)2CH3, wherein the methyl, ethyl, C(=O)CH3 or S(O)2CH3 is optionally R 3b replace; and / or R 3b Selected from halogens.
4. The compound of formula (I) according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein, X is selected from N or CR x Y is selected from N or CR y Z is selected from N or CR z The condition is that X, Y, and Z are not simultaneously N; or X is selected from N, Y is selected from N, and Z is selected from CR. z ; and / or R z Selected from H, halogen, amino, C1-C6 alkyl or NHC(=O)C1-C6 alkyl; or R z Selected from H.
5. The compound of formula (I) according to any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein, L 1 Selected from bond, O, S, or NR; or L 1 It is O.
6. The compound of formula (I) according to any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein, R 1 Selected from C3-C8 cycloalkyl, C1-C6 alkyl, C6-C 10 aryl, 5-6 membered heteroaryl or 5-6 membered heterocyclic, wherein the C3-C8 cycloalkyl, C1-C6 alkyl, C6-C 10 Aryl, 5-6 membered heteroaryl or 5-6 membered heterocyclic group are optionally replaced by R 1a Replace, R 1a Selected from halogen, deuterium, cyano, hydroxyl, amino, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, oxo, -S-C1-C6 alkyl, -O-C3-C8 cycloalkyl, -S-C3-C8 cycloalkyl, or carboxyl; or R 1 Selected from C3-C8 cycloalkyl, C6-C 10 aryl or 5-6-membered heteroaryl, wherein the C3-C8 cycloalkyl, C6-C 10 Aryl or 5-6 quinone heteroaryl groups are selectively substituted with R. 1a Replace; or R 1 Selected from C6-C 10 aryl; or R 1 Selected from phenyl.
7. The compound of formula (I) according to any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein, R 2 Selected from C1-C6 alkyl, amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, NH(C3-C8 cycloalkyl), N(C1-C6 alkyl)(C3-C8 cycloalkyl), C2-C6 alkenyl, -S-C1-C6 alkyl, or C1-C6 alkoxy, wherein the C1-C6 alkyl, amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, NH(C3-C8 cycloalkyl), N(C1-C6 alkyl)(C3-C8 cycloalkyl), C2-C6 alkenyl, -S-C1-C6 alkyl, or C1-C6 alkoxy is optionally R 2a Replace; or R 2 Selected from C1-C4 alkyl groups, wherein the C1-C4 alkyl groups are optionally R 2a replace; and / or R 2a Selected from hydroxyl, halogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, cyano, amino, or -S-C1-C6 alkyl, wherein the C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, amino, or -S-C1-C6 alkyl is optionally R 2b Replace; or R 2a Selected from halogens or C3-C4 cycloalkyl groups.
8. The compound of formula (I) according to any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein, L 2 Selected from -C(=O)NH-, -C(=S)NH-, Or -S(=O)2NH-; or L 2 Selected from -C(=O)NH-.
9. The compound of formula (I) according to any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein, Q is selected from Q 1 Q 1 yes in, represent It is either (Z) configuration or (E) configuration; or Q 1 yes and / or X 3 Selected from O or NH; and / or R 4 Selected from C1-C6 alkyl, C3-C6 cycloalkyl, or 4-6 membered heterocyclic groups, wherein the C1-C6 alkyl, C3-C6 cycloalkyl, or 4-6 membered heterocyclic group is optionally R 4a Replace, where R 4a Selected from halogen, cyano, hydroxyl, amino, C1-C6 alkyl, or C1-C6 alkoxy; or R 4 Selected from C1-C6 alkyl or 4-6 membered heterocyclic groups; or R 4 Selected from C1-C3 alkyl groups; or R 4 Selected from methyl.
10. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein, The compound of formula (I) is selected from the following compounds:
11. A pharmaceutical composition comprising the compound of any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
12. Use of the compound of any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 11, in the preparation of a medicament for inhibiting WRN.
Citation Information
Cited By
Formamide compound having WRN inhibitory effect and use thereof
WO2026119262A1
